

*1

Material Safety Data Sheet

CELLCEPT(R) Capsules (250 mg)

1. Product and Company Identification

Product name CELLCEPT(R) Capsules (250 mg)

Product code SAP-10133839

Use - pharmaceutical active substance (immunosuppressant)

Company information Enquiries:

Hoffmann-La Roche Inc. 340 Kingsland Street USA-Nutley, N.J. 07110-1199

United States of America

Phone 001-973/235 50 00 E-Mail info.sds@roche.com

US Emergency phone: (800)-827-6243 US Chemtrec phone: (800)-424-9300

*1 referring to: Mycophenolate mofetil

2. Hazard identification

Emergency Overview

Form capsules

Color brown

blue

Hazard Overview - May cause allergic reactions.

- Harmful if swallowed.

- May cause birth defects based on animal data.

Potential Health Effects - Exposure: Inhalation, Ingestion, Skin contact, Eye contact

- Target Organs: eye, skin, gastrointestinal system, Immune System

 Acute Effects: May cause eye irritation., May cause skin irritation., This material has not been tested as a whole; therefore, the information described below is based on one or more of its ingredients., May cause gastrointestinal effects., Signs and symptoms may include nausea, vomiting, diarrhea, constipation,

cramps, and loss of appetite.

- Chronic Effects: May cause allergic reactions., May cause

immune system suppression.

- Carcinogenicity: formulation not listed by NTP, IARC or OSHA

Date: 27.12.11/LS (SEISMO) Replacing edition of: 13.10.11 Page: 1/8

GHS Classification

Health Hazards:

3.1 oral Acute toxicity (Category 4) H302 Harmful if swallowed.

3.5 Germ cell mutagenicity (Category 2)
H341 Suspected of causing genetic defects.

3.7 D Reproductive toxicity (Category 1B)
H360D May damage the unborn child.

3.9 Specific target organ toxicity - Repeated exposure (Category 1)

H372 Causes damage to organs.

Signalword: Danger

Label:



Precautionary statements:

- P201 Obtain special instructions before use.
- P260 Do not breathe dust
- P273 Avoid release to the environment.
- P301 + P310 IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
- P308 + P313 IF exposed or concerned: Get medical advice/attention.
- P405 Store locked up.

Additional Health Information

- Reproductive Toxicity: May cause birth defects based on animal data. Since this material may affect the developing fetus, females planning to have a child and pregnant women should exercise caution regarding exposure.
- It is also advisable for nursing mothers to exercise caution regarding exposure.

3. Composition/Information on ingredients

Characterization pharmaceutical product not ready for use

Ingredients	Concentration	
Mycophenola CAS:	ate mofetil 128794-94-5	~ 83 %
Starch CAS:	9005-84-9	~ 10 %
Povidone K 9 CAS:	90 9003-39-8	~ 2 %
Magnesium s CAS:	stearate 557-04-0	~ 2 %

Date: 27.12.11/LS (SEISMO) Replacing edition of:

4. First-aid measures

Eye contact - rinse immediately with tap water for 10 minutes - open eyelids

forcibly

Skin contact - drench affected skin with water

Inhalation - remove the casualty to fresh air

- in the event of symptoms get medical treatment

Ingestion - consult physician

Note to physician - treat symptomatically

5. Fire-fighting measures

Suitable extinguishing media - adapt extinguishing media to surrounding fire conditions

Flash point (liquid) not applicable

Specific hazards - Toxic emissions may be given off in a fire

Protection of fire-fighters - precipitate gases/vapours/mists with water spray

6. Accidental release measures

Environmental protection - do not allow to enter drains or waterways

- if the substance reaches waters or the sewer system, inform the

competent authority

- the solvent should be held back due to environmental protection

Methods for cleaning up - collect spilled material (avoid dust formation) and hand over to

waste removal in sealed containers

7. Handling and storage

Handling

Technical measures - no special measures necessary if stored and handled as

prescribed

Storage

Storage conditions - keep containers tightly closed

room temperaturestore in a dry placeprotected from light

Packaging materials - drums

- lined with polyethylene bag

Date: 27.12.11/LS (SEISMO) Replacing edition of: 13.10.11 Page: 3/8

8. Exposure controls/Personal protection **Engineering Measures** - see 7. Monitoring Threshold value (USA) air - ACGIH-TLV: 10 mg/m3 *2 - ACGIH-TLV: 10 mg/m3 (not classifiable as a human carcinogen) *3 - OSHA-PEL: 5 mg/m3 (respirable fraction) *3 - OSHA-PEL: 15 mg/m3 (total dust) *3 - NIOSH-REL: 5 mg/m3 (respirable fraction) *3 - NIOSH-REL: 15 mg/m3 (total dust) *3 Threshold value (Roche) air - IOEL (Internal Occupational Exposure Limit): 0.01 mg/m3 *1 Analytics - sampling on glass fibre filter, desorption with methanol; basify with NaOH, heat; neutralize with HCI, HPLC analysis Personal protective equipment Respiratory protection - Respiratory protection is recommended as a precaution to minimize exposure. Effective engineering controls are considered to be the primary means to control worker exposure. Respiratory protection should not substitute for feasible engineering controls. - respiratory protection not necessary during normal operations Hand protection - protective gloves (eg made of neoprene, nitrile or butyl rubber) Eve protection - safety glasses referring to: Mycophenolate mofetil *2 referring to: Magnesium stearate referring to: Starch 9. Physical and chemical properties Color brown blue Form capsules Solubility ≤ 22 mg/l, water (~ 22 °C, pH 6.3, HPLC, 24 h) ≤36 mg/l, aquatic ecotoxicity media (~22 °C, HPLC, 24 h) *1 Partition coefficient log Pow 1.45 (n-octanol/water) pH 7.4 Mycophenolate mofetil referring to: 10. Stability and reactivity Stability - stable under the conditions mentioned in chapter 7

 Date:
 27.12.11/LS (SEISMO)
 Replacing edition of:
 13.10.11
 Page: 4/8

- warming Conditions to avoid - light - humidity Materials to avoid - strong oxidizing agents *1 referring to: Mycophenolate mofetil 11. Toxicological information Acute toxicity - LD₅₀ 353 mg/kg (oral, rat); females, "trimmed Spearman-Karber method" *1 - LD₅₀ 500 (oral, rat); males, "trimmed mg/kg Spearman-Karber method" *1 - LD₀ 250 (oral, rat) *1 mg/kg - LD₅₀ > 2'000 mg/kg (oral, rat) *2 Local effects - skin: non-irritant *1 eye: non-irritant *1 Sensitization *1 - non-sensitizing Mutagenicity - mutagenic (OECD No. 474 (Micronucleus Test)); threshold dose response *4 - mutagenic (mouse lymphoma cell mutation test; OECD No. 476 (Mammalian Cell Gene Mutation Test)) *4 does not induce chromosomal aberrations in vitro (OECD No. 473 (Mammalian Cytogenic Test)) not mutagenic (Ames test) *4 Carcinogenicity not carcinogenic (several species) *1 Reproductive toxicity - teratogenic (several species) *1 Note - immunosuppressive agent *1 average therapeutic dose 1 g twice daily *1 - elimination half-life: 16-18 h *1 excretion predominantly renal *1 adverse effects at therapeutic dose: diarrhea, drop in white blood cell count, susceptibility to infections, vomiting *1 - high doses may irritate the digestive tract *1 referring to: Mycophenolate mofetil referring to: Magnesium stearate Mycophenolic acid referring to: 12. Ecological information Ready biodegradability not readily biodegradable ~ 14 %, 64 d (FDA Technical Assistance Document No. 3.11) *1 not readily biodegradable primary degradation evidenced by HPLC < 6 %, 28 d (Manometric Respirometry Test, OECD No. 301 F) *1

Date: 27.12.11/LS (SEISMO) Replacing edition of: 13.10.11 Page: 5/8

Inherent biodegradability -	evidence for medium-term biodegradation in surface waters (analogous to OECD 308, Transformation in natural water/sediment systems)	*1
Abiotic degradation -	rapid degradation, photodegradation, hydrolysis 22.3 mg/l, water; HPLC \sim 37 %, 120 h, \sim 22 °C, dark \sim 67 %, 120 h, \sim 22 °C, under illumination	*1
-	adaptation/recovery of organisms upon prolongation of test duration (Scenedesmus (=Desmodesmus) subspicatus) LOEC (14 d) 1.6 mg/l (nominal concentration) (OECD No. 201, prolonged) barely toxic for planktonic crustaceans (nominal concentration = 100 mg/l), test performed with water accommodated fractions (Daphnia magna)	*1 *1
Air pollution -	observe local/national regulations	*1
*1 referring to:	Mycophenolate mofetil	
13. Disposal considerations		
-	incinerate in qualified installation with flue gas scrubbing observe local/national regulations regarding waste disposal DO NOT FLUSH unused medications or POUR them down a sink or drain. If available in your area, use takeback programs run by household hazardous waste collection programs or community pharmacies to dispose of unused and expired medicines. If you don't have access to a takeback program, dispose of these medicines in the household trash by removing them from their original containers and mixing them with an undesirable substance, such as used coffee grounds or kitty litter.	

Date: 27.12.11/LS (SEISMO) Replacing edition of: 13.10.11 Page: 6/8

14. Tra	nsport info	rmation	l					
IATA	Class	UN/ID	PG		PI	Label	Mark	
	9	3077	III		956/956	9	EHS	
IMDG	Class	UN	PG	EmS	PI	Label Mark		
	9	3077	III	F-A S-F	P002/IBC08	9	marine pollutant	
RID/ADR	Class	UN	PG	Haz.no	PI	Label	Mark	Classif.
	9	3077	Ш	90	P002/IBC08	9	EHS	M7
		•						
DOT	Class	UN/ID	PG	PI	RQ	Label	Haz.no	
	9	3077	Ш			9		
DOT Rer	nark:		TRA	ANSPORTI	ATED IN NON-BULI ED BY MOTOR VE 9CFR 171.4(c)).			
Proper sh	nipping name		ENVI	RONMENT	ALLY HAZARDOU	S SUBSTANCE,	, SOLID, N	.O.S.
Technica	l name		Myco	phenolate r	mofetil			
15. Reg	julatory info	ormatio	n					
TSCA Sta	atus		- FD	A Exemptic	n - not on inventory	,		
Reporting Requirements			 The United States Environmental Protection Agency (USEPA) has not established a Reportable Quantity (RQ) for releases of this material. In New Jersey, report all releases which are likely to endanger the public health, harm the environment or cause a complaint to the NJDEPE Hotline (1-609-292-5560) and to local officials. 					

Date: 27.12.11/LS (SEISMO) Replacing edition of: 13.10.11 Page: 7/8

- State and local regulations vary and may impose additional reporting requirements.

16. Other information Safety-lab number - BS-8818 *1 - BS-9333 *1 Edition documentation - changes from previous version in sections 8 referring to: Mycophenolate mofetil

Date: 27.12.11/LS (SEISMO) Replacing edition of: 13.10.11 Page: 8/8

The information in this safety data sheet is based on current scientific knowledge. It should not be

taken as expressing or implying any warranty concerning product characteristics.